KDR and cancer: VEGFA‒VEGFR2 inhibitors can be classified into two categories based on their targets: drugs that directly inhibit VEGFA, such as bevacizumab and VEGFA trap versus tyrosine kinase inhibitors (TKIs) that inhibit VEGFR2, such as sorafenib, lenvatinib, apatinib, regorafenib [2], etc. Inhibition of the VEGFA/VEGFR2 pathway has shown remarkable efficacy in improving the prognosis of patients with cancer.